Literature DB >> 10231847

Dissociated insulin and islet amyloid polypeptide secretion from isolated rat pancreatic islets cocultured with human pancreatic adenocarcinoma cells.

F Wang1, T E Adrian, G Westermark, T Gasslander, J Permert.   

Abstract

Abnormal insulin and islet amyloid polypeptide (IAPP) secretion are usually seen in patients with exocrine pancreatic cancer. The beta-cell dysfunction is a characteristic of the glucose intolerance found in pancreatic cancer patients. The effects of pancreatic cancer cells on insulin and IAPP secretion from beta cells are unclear. In this study, isolated rat pancreatic islets were cocultured with two human pancreatic adenocarcinoma cell lines (Panc-1 and HPAF) and a human colonic adenocarcinoma cell line (HT-29). As a control, islets were incubated in the absence of malignant cells. The accumulation of insulin and IAPP in culture media was measured by radioimmunoassay. Output of insulin and IAPP was decreased in islets cocultured with each malignant cell line. Molar ratio of secreted IAPP and insulin (IAPP/insulin) was increased in the islets cocultured with Panc-1 or HPAF cells, but not HT-29 cells. The decreased insulin and IAPP secretion were partly recovered after Panc-1, HPAF, or HT-29 cells were removed. The IAPP/insulin ratio was normalized after the removal of Panc-1 or HPAF cells. This study indicates that insulin and IAPP secretion are altered by the human adenocarcinoma cells investigated. The impairment induced by pancreatic adenocarcinoma cells is associated with a hypersecretion of IAPP relative to insulin on a molar basis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10231847     DOI: 10.1097/00006676-199905000-00012

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  6 in total

1.  Diabetes and pancreatic cancer.

Authors:  Donghui Li
Journal:  Mol Carcinog       Date:  2012-01       Impact factor: 4.784

2.  Baseline hemoglobin-A1c impacts clinical outcomes in patients with pancreatic cancer.

Authors:  Katherine Y Fan; Avani S Dholakia; Aaron T Wild; Zheng Su; Amy Hacker-Prietz; Rachit Kumar; Mary Hodgin; Charles C Hsu; Dung T Le; Ana De Jesus-Acosta; Luis A Diaz; Daniel A Laheru; Ralph H Hruban; Elliot K Fishman; Todd D Brown; Timothy M Pawlik; Christopher L Wolfgang; Phuoc T Tran; Joseph M Herman
Journal:  J Natl Compr Canc Netw       Date:  2014-01       Impact factor: 11.908

Review 3.  New insights into pancreatic cancer-induced paraneoplastic diabetes.

Authors:  Raghuwansh P Sah; Sajan Jiv Singh Nagpal; Debabrata Mukhopadhyay; Suresh T Chari
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-03-26       Impact factor: 46.802

4.  Adrenomedullin is up-regulated in patients with pancreatic cancer and causes insulin resistance in β cells and mice.

Authors:  Gaurav Aggarwal; Vijaya Ramachandran; Naureen Javeed; Thiruvengadam Arumugam; Shamit Dutta; George G Klee; Eric W Klee; Thomas C Smyrk; William Bamlet; Jing Jing Han; Natalia B Rumie Vittar; Mariza de Andrade; Debabrata Mukhopadhyay; Gloria M Petersen; Martin E Fernandez-Zapico; Craig D Logsdon; Suresh T Chari
Journal:  Gastroenterology       Date:  2012-09-06       Impact factor: 22.682

Review 5.  The relationship between diabetes and pancreatic cancer.

Authors:  Feng Wang; Margery Herrington; Jörgen Larsson; Johan Permert
Journal:  Mol Cancer       Date:  2003-01-06       Impact factor: 27.401

6.  Tumor-insular Complex in Neoadjuvant Treated Pancreatic Ductal Adenocarcinoma Is Associated With Higher Residual Tumor.

Authors:  Iván A González; Liang-I Kang; Gregory A Williams; Jingxia Liu; David G DeNardo; William G Hawkins; Deyali Chatterjee
Journal:  Am J Surg Pathol       Date:  2020-06       Impact factor: 6.298

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.